Photocure’s Cevira shows positive interim results for treatment of precancerous lesions of the cervix
Six-month interim data presented at international conference addressing prevention of cervical cancer
Photocure presented positive interim data at the six-month follow up stage of its phase I/II clinical feasibility study with Cevira™ at the EUROGIN 2008 international conference. Cevira™ is Photocure’s photodynamic therapy (PDT) in development as a new treatment of precancerous lesions of the cervix (CIN) induced by persistent human papilloma virus (HPV) infection.
The six-month clinical data from 35 patients in Norway showed that 73% patients with moderate grade lesions (CIN2) were treated successfully as determined by complete regression of lesions confirmed through a normal biopsy (histology) and cell sampling (cytology). 38% of patients with more severe (CIN3) lesions also responded positively to Cevira treatment.
A complete response of the lesions correlated with the eradication of HPV in 87% of the responding patients. Importantly, the treatment was well tolerated with cervical tissue preserved and completely normalized after PDT treatment.
Cevira PDT is being studied in women with cervical precancerous lesions who are eligible for surgery to remove the affected tissues, the current standard of care. The ongoing study involves 92 patients at two clinical centers in Germany and Norway, all of whom will be followed for 12 months after treatment.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

BASF dedicates global dermatology lab
MediGene announces corporate restructuring and aims to strengthen pipeline
NYU Langone Medical Center and School of Medicine - New York City, USA

University of Texas Health Science Center at San Antonio - San Antonio, USA
Immune system reveals new ways to treat brain disease and pain
Vibrations key to efficiency of green fluorescent protein - Charting femtosecond energy flow could aid redesign of molecules to improve light capture

First microarrayed 3D neuronal culture platform developed

AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus

64 human genomes as new reference for global genetic diversity - The new reference data provide an important basis: The aim is to estimate the individual risk of developing certain diseases such as cancer
Psilocybin eases existential anxiety in people with life-threatening cancer
Novartis Phase III study shows once-daily NVA237 is superior to placebo and similar to tiotropium in improving lung function in COPD - GLOW2 study shows NVA237 provides superior 24-hour bronchodilation to placebo (p
